Impaired high-density lipoprotein function in patients with heart failure by Emmens, Johanna E. et al.
                                                                    
University of Dundee
Impaired high-density lipoprotein function in patients with heart failure
Emmens, Johanna E.; Jia, Congzhuo; Ng, Leong L.; van Veldhuisen, Dirk J.; Dickstein,
Kenneth; Anker, Stefan D.
Published in:
Journal of the American Heart Association
DOI:
10.1161/JAHA.120.019123
Publication date:
2021
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Emmens, J. E., Jia, C., Ng, L. L., van Veldhuisen, D. J., Dickstein, K., Anker, S. D., Lang, C. C., Cleland, J. G.
F., Voors, A. A., de Boer, R. A., & Tietge, U. J. F. (2021). Impaired high-density lipoprotein function in patients
with heart failure. Journal of the American Heart Association, 10(9), [e019123].
https://doi.org/10.1161/JAHA.120.019123
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 29. May. 2021
Journal of the American Heart Association
J Am Heart Assoc. 2021;10:e019123. DOI: 10.1161/JAHA.120.019123 1
 
ORIGINAL RESEARCH
Impaired High- Density Lipoprotein Function 
in Patients With Heart Failure
Johanna E. Emmens , MD*; Congzhuo Jia , MD*; Leong L. Ng, MD; Dirk J. van Veldhuisen, MD, PhD; 
Kenneth Dickstein, MD, PhD; Stefan D. Anker, MD, PhD; Chim C. Lang, MD; Gerasimos Filippatos, MD; 
John G. F. Cleland, MD, PhD; Marco Metra, MD, PhD; Adriaan A. Voors, MD, PhD; Rudolf A. de Boer , MD, PhD†; 
Uwe J. F. Tietge, MD, PhD†
BACKGROUND: We recently showed that, in patients with heart failure, lower high- density lipoprotein (HDL) cholesterol con-
centration was a strong predictor of death or hospitalization for heart failure. In a follow- up study, we suggested that this as-
sociation could be partly explained by HDL proteome composition. However, whether the emerging concept of HDL function 
contributes to the prognosis of patients with heart failure has not been addressed.
METHODS AND RESULTS: We measured 3 key protective HDL function metrics, namely, cholesterol efflux, antioxidative ca-
pacity, and anti- inflammatory capacity, at baseline and after 9 months in 446 randomly selected patients with heart failure 
from BIOSTAT- CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure). Additionally, the relationship 
between HDL functionality and HDL proteome composition was determined in 86 patients with heart failure. From baseline 
to 9 months, HDL cholesterol concentrations were unchanged, but HDL cholesterol efflux and anti- inflammatory capacity 
declined (both P<0.001). In contrast, antioxidative capacity increased (P<0.001). Higher HDL cholesterol efflux was associ-
ated with lower mortality after adjusting for BIOSTAT- CHF risk models and log HDL cholesterol (hazard ratio, 0.81; 95% CI, 
0.71– 0.92; P=0.001). Other functionality measures were not associated with outcome. Several HDL proteins correlated with 
HDL functionality, mainly with cholesterol efflux. Apolipoprotein A1 emerged as the main protein associated with all 3 HDL 
functionality measures.
CONCLUSIONS: Better HDL cholesterol efflux at baseline was associated with lower mortality during follow- up, independent of 
HDL cholesterol. HDL cholesterol efflux and anti- inflammatory capacity declined during follow- up in patients with heart failure. 
Measures of HDL function may provide clinical information in addition to HDL cholesterol concentration in patients with heart 
failure.
Key Words: cholesterol efflux ■ functionality ■ high- density lipoprotein ■ outcome ■ proteome
Recently, we showed that low high- density lipo-protein (HDL) cholesterol was among the stron-gest predictors of death or hospitalization for 
heart failure (HF) in 2 large European HF cohorts.1 In 
addition, low concentrations of HDL cholesterol have 
been associated with a higher incidence of HF2,3 and 
worse outcomes in patients with established HF.3– 6 In 
contrast, HDL cholesterol– increasing therapies have 
failed to show clear benefit, casting doubt on whether 
HDL cholesterol, as conventionally measured, can 
be ascribed a causal protective role.7 However, HDL 
has high proteomic complexity and a wide range of 
biological effects,8,9 including antioxidative, cholesterol 
efflux– promoting, anti- inflammatory, antiapoptotic, and 
endothelial- protective effects.6 Since inflammation and 
oxidative stress are common in HF,10 the antioxidative 
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and anti- inflammatory properties of HDL might be an 
endogenous defense mechanism. These attributes of 
HDL are not captured by simply measuring conven-
tional HDL cholesterol concentrations.
We have shown that HDL proteome composi-
tion is strongly associated with prognosis in pa-
tients with HF. The biggest differences were seen 
in proteins reflecting crosslinking of actin filaments, 
alveolar- capillary membrane function, inflammation, 
and oxidative stress.11 HDL function might also have 
prognostic implications.12– 15 Previous studies in-
cluded relatively few patients (ranging from 23 to 320 
patients), did not have follow- up measurements, and 
did not correct for many potential confounders. Also, 
changes in HDL functionality as patients recover from 
an episode of worsening HF have not been studied. 
Finally, whether shifts in HDL proteome composition 
are associated with changes in function is largely 
unexplored.
We investigated 3 measures of HDL function 
(HDL cholesterol efflux, antioxidative capacity, and 
anti- inflammatory capacity) in patients with worsen-
ing HF, their changes after 9 months of treatment, and 
their associations with prognosis.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Patient Population
For the present study, 446 patients were randomly 
selected from the index cohort of BIOSTAT- CHF 
(A Systems Biology Study to Tailored Treatment in 
Chronic Heart Failure), which has been described in 
detail before.16 A comparison between the present 
study cohort and the overall BIOSTAT- CHF cohort is 
provided in Table S1. In brief, BIOSTAT- CHF was an 
investigator- driven, multicenter clinical study consist-
ing of 2516 patients with HF, which aimed to identify 
patients with a poor outcome despite currently recom-
mended treatment. Patients who presented with either 
new- onset or worsening HF, which was defined as left 
ventricular ejection fraction ≤40% or B- type natriu-
retic peptide >400  pg/mL or NT- proBNP (N- terminal 
pro- B- type natriuretic peptide) >2000 pg/mL, were in-
cluded. Patients were encouraged to be up- titrated to 
recommended treatment doses.17 All patients enrolled 
in BIOSTAT- CHF provided written informed consent. 
BIOSTAT- CHF was conducted in compliance with the 
Declaration of Helsinki, national ethics and legal re-
quirements, and relevant EU legislation. The study also 
received approval by national and local ethics commit-
tees of all involved centers.
Additionally, 86 patients from BIOSTAT- CHF 
with available data on proteomic analysis of HDL- 
associated proteins at baseline were included in 
the present study (baseline characteristics in Table 
S2, including differences between this cohort and 
the HDL functionality cohort and BIOSTAT- CHF pa-
tients without proteomic data available), for which 
detailed methodology (including selection proce-
dure) and results have been published previously.11 In 
brief, lipoproteins were isolated from whole plasma 
using calcium silicate matrix, reduced using tris 
(2- carboxyethyl) phosphine, alkylated by iodoacet-
amide, denatured using ammonium deoxycholate, 
and trypsin digested. Solid- phase extraction was 
performed, and samples were reconstituted and 
spiked with an internal standard to allow for absolute 
quantification. Data were normalized to the volume 
of plasma by injecting a constant amount of 1 μL of 
plasma for each sample. Samples were then ana-
lyzed in triplicate on nanoscale liquid chromatogra-
phy coupled with mass spectrometry, with quality 
CLINICAL PERSPECTIVE
What Is New?
• High- density lipoprotein (HDL) cholesterol efflux 
and anti- inflammatory capacity significantly de-
creased over time in patients with HF, possibly sig-
nifying a “state of no return” for HDL functionality.
• Better HDL cholesterol efflux at baseline is as-
sociated with lower mortality during follow- up 
in heart failure, independent of HDL cholesterol 
and other relevant clinical factors.
• Apolipoprotein A1 emerged as an important 
protein that is associated with all 3 measures of 
HDL functionality.
What Are the Clinical Implications?
• Measures of HDL function (HDL quality), may 
provide clinical information beyond static HDL 
cholesterol concentration (HDL quantity) in pa-
tients with heart failure.
• In patients with heart failure, HDL cholesterol 
efflux might be a clinically relevant target as-
pect of HDL functionality for future therapeutic 
intervention.
Nonstandard Abbreviations and Acronyms
BIOSTAT- CHF A Systems Biology Study to 
Tailored Treatment in Chronic 
Heart Failure
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controls after every 10 samples. Raw data were in-
terrogated by Progenesis QI software (Nonlinear 
Dynamics, Gateshead, UK), which executed label- 
free quantification of the identified proteins using 
the Hi- N3 method. Analyses were focused on Hi- N 
relative quantification, with the Hi- N absolute quan-
tification method serving as a verification backup if 
needed. The proteins that were previously found to 
have the strongest association with outcome in this 
cohort were updated according to available newly re-
viewed data.18
Sensitivity analyses were performed in patients with 
HF with preserved ejection fraction (left ventricular 
ejection fraction > 45%) and patients with chronic kid-
ney disease (defined as estimated glomerular filtration 
rate <60 mL/min per 1.73 m2). Treatment optimization 
with angiotensin- converting enzyme inhibitors and 
beta blockers was graded according to achievement 
of 4 different levels of treatment dose, as described be-
fore.17 The influence of statin dose on HDL functionality 
was studied by calculating statin dose in simvastatin 
equivalent, where 40 mg of simvastatin corresponded 
to 20  mg of atorvastatin, 5  mg of rosuvastatin, and 
80 mg of pravastatin.19
Study Design and Laboratory 
Measurements
The blood samples were collected by venipuncture and 
stored at −80˚C. Blood measurements were performed 
directly on the basis of standardized international 
methods if possible; otherwise, they were performed 
by a central laboratory. Interleukin- 6 and endothelin-
 1 were measured in frozen plasma by Singulex Inc. 
(Alameda, CA) using high- sensitivity single molecule 
counting technology (Research Use Only, Erenna 
Immunoassay System; Singulex). Measurement of ad-
ditional blood biomarkers was performed as previously 
described.20,21
In both study cohorts, 3 metrics of HDL functionality 
were measured at baseline and also after 9 months 
for the larger study cohort of 446 patients. The assays 
for cholesterol efflux, antioxidative capacity, and anti- 
inflammatory capacity are established assays that have 
been used in large cohorts before22,23 and have been 
described in detail previously.24 Each measurement 
was carried out at the same time for all patient samples 
to reduce potential experimental variation attributable 
to differing assay conditions. In brief, HDL was isolated 
from EDTA plasma by precipitation of apolipoprotein 
B– containing lipoproteins as described.22
HDL cholesterol efflux was measured by differ-
entiating THP- 1 human monocytes (ATCC via LGC 
Promochem, Teddington, UK) into macrophages and 
loading them with 50 µg/mL acetylated low- density li-
poprotein (LDL) and 1 µCi/mL 3H- cholesterol (Perkin 
Elmer, Boston, MA) for 24 hours. Afterwards, the mac-
rophages were equilibrated for 18  hours in Roswell 
Park Memorial Institute 1640 medium followed by ad-
dition of 2% of individual apolipoprotein B– depleted 
plasma samples for 5 hours. Then, an aliquot of the 
medium was counted for quantification of effluxed 
cholesterol label (1600CA Tri- Carb; Packard, Meriden, 
CT). After washing and incubation with 0.1 M NaOH for 
30 minutes, the radioactivity remaining within the cells 
was also determined with liquid scintillation counting. 
Efflux was expressed as the percentage of counts 
released into the medium relative to the total dose of 
initial radioactivity present. Values were corrected for 
nonspecific non– HDL- mediated efflux and corrected 
for potential plate- to- plate variations by a standard 
curve constructed using different HDL concentrations 
from pooled plasma of healthy donors. The intra- assay 
coefficient of variation of this assay is 5.7%.
The antioxidative capacity of HDL was assessed by 
measuring the capacity of HDL to inhibit native LDL 
oxidation. LDL was isolated from plasma of a fasted 
healthy male donor using sequential ultracentrifugation 
and oxidized with 5- mM AAPH for 24 hours either in 
the presence of 2% of the individual HDL preparations 
or a PBS control. After protein precipitation by using 
10% trichloroacetic acid, the accumulation of thiobar-
bituric acid reactive substances was determined as 
a measure for oxidative modification.24 Antioxidative 
capacity of HDL was expressed as the number of 
thiobarbituric acid reactive substances accumulated 
relative to control LDL oxidized in the absence of HDL. 
The intra- assay coefficient of variation of this assay is 
7.1%.
The anti- inflammatory capacity of HDL was as-
sessed using human umbilical vein endothelial cells 
(Endothelial Cell Core Facility of the University Medical 
Center Groningen). Human umbilical vein endothelial 
cells s were preincubated with either 2% of HDL or 
a PBS control for 30 minutes. Subsequently, 10  ng/
mL tumor necrosis factor- α (R&D Systems, Abingdon, 
UK) was added and incubated for 5 hours. Then, RNA 
was isolated with Trizol (Invitrogen, Carlsbad, CA), and 
vascular cell adhesion molecule- 1 mRNA expression 
levels were determined by quantitative real- time poly-
merase chain reaction using cyclophilin as a house-
keeping gene essentially as published.23,24 Values are 
expressed as percent reduction achieved by the ad-
dition of HDL as compared with the full vascular cell 
adhesion molecule- 1 induction by tumor necrosis fac-
tor- α. The intra- assay coefficient of variation of this 
assay is 7.2%.
All analyses were performed at least in duplicate. 
For all HDL function assays, we demonstrated previ-
ously that the results are identical when comparing 
fresh with frozen plasma.24 Further, we demonstrated 
dependency of the results on the presence of HDL in 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
J Am Heart Assoc. 2021;10:e019123. DOI: 10.1161/JAHA.120.019123 4
Emmens et al High- Density Lipoprotein Function in Heart Failure
apolipoprotein B– depleted plasma; in all 3 assays apo-
lipoprotein B– depleted plasma from which HDL had 
been additionally removed by ultracentrifugation had 
no significantly different biological activity from the re-
spective control conditions.24 In addition, for all HDL 
function assays, the chosen concentrations are within 
the linear range of the respective assays.
Study End Points
The relation of HDL functionality with 3 clinical out-
comes was investigated: all- cause mortality, unsched-
uled HF hospitalization, and a composite outcome of 
all- cause mortality and HF hospitalization. The end 
points were adjusted for the BIOSTAT- CHF risk mod-
els created for each specific outcome in this cohort. 
The BIOSTAT- CHF risk models included age, log blood 
urea nitrogen, log NT- proBNP, hemoglobin, and beta- 
blocker use at baseline for all- cause mortality; age, HF 
hospitalization in the previous year, peripheral edema, 
systolic blood pressure, and estimated glomerular fil-
tration rate for HF hospitalization; and age, HF hospi-
talization in the previous year, systolic blood pressure, 
log NT- proBNP, hemoglobin, HDL cholesterol, sodium, 
and beta- blocker use at baseline for the combined end 
point.1
Statistical Analysis
Descriptive statistics were used to examine the base-
line characteristics of the study population at base-
line and 9 months. Data are presented as means±SD 
when continuous normally distributed, as medians 
(interquartile range) when skewed, and as frequen-
cies (percentage) when categorical. Continuous 
normally distributed variables were tested with the 
Student independent t- test, skewed variables using 
the Mann- Whitney U test, and categorical variables 
using chi- squared tests (Tables S1 and S2). Paired 
testing was applied to Table 1 using paired t- test, 
Wilcoxon test for paired samples, or McNemar test 
for paired samples when variables were continu-
ous normally distributed, skewed, or categorical, 
respectively. Adjustments for multiple testing were 
applied using the Bonferroni method. Predictors of 
HDL functionality were analyzed using univariable 
and multivariable regression analyses, in which all 
variables with P<0.1 in univariable analysis were in-
cluded in multivariable analysis and subjected to the 
backward elimination method. Variables with P<0.05 
were included in the final multivariable regression 
model. Before linear regression analysis, the as-
sumption of normal distribution of residuals and lin-
ear relationship was checked, as well as checks for 
outliers. If appropriate, variables were logarithmically 
transformed (using natural logarithm). Cox propor-
tional hazard models were constructed for all 3 end 
Table 1. Baseline Characteristics of the HDL Functionality 
Cohort at Baseline and After 9 Months*
Baseline
Change From 
Baseline to 9 
Months P Value
Clinical characteristics
Age, y 68±12 0.75±0 NA
Sex (male), n (%) 283 (74) NA
NYHA classification (III/
IV), n (%)
199 (53) −117 (−31) <0.001
Systolic blood pressure, 
mm Hg
124±20 −0.06±22.9 0.961
Diastolic blood pressure, 
mm Hg
75±13 −0.79±15.1 0.308
Heart rate, bpm 81±21 −5±24 <0.001
LVEF, n (%) 30 (25– 35) 5 (0 to 11) <0.001
HFpEF/LVEF >45%, n (%) 6 (3) 18 (10) <0.001
Diabetes mellitus, n (%) 103 (27) NA
Smoking (past or 
current), n (%)
250 (65) NA
Primary heart failure etiology, n (%)
Ischemic heart disease 168 (44) NA
Hypertension 38 (10) NA
Cardiomyopathy 92 (24) NA
Valvular disease 28 (7) NA
Medication, n (%)
ACE inhibitor/ARB 286 (75) +52 (+13) <0.001
≥50% target dose† 160 (42) +68 (+18) <0.001
100% target dose† 52 (14) +55 (+14) <0.001
Beta blocker 330 (86) +26 (+13) <0.001
≥50% target dose† 116 (30) +50 (+13) <0.001
100% target dose† 52 (14) +5 (+1) <0.001
Loop diuretics 382 (99) −34 (−8) <0.001
MRA 206 (54) +19 (+5) 0.005
Statins (total) 200 (52) −11 (−3) 0.127
Simvastatin 84 (42) −2 (+1)
Atorvastatin 80 (40) −5 (0)
Rosuvastatin 19 (10) −2 (−1)
Pravastatin 15 (8) −1 (−1)
Fluvastatin 2 (0) −1 (0)
Laboratory values
Hemoglobin, g/dL 13.5±1.8 −0.2±1.5 0.078
Sodium, mmol/L 140 (137– 142) 0 (−2 to 2) 0.735
Potassium, mmol/L 4.2 (3.9– 4.5) 0.1 (−0.2 to 0.5) <0.001
ASAT, U/L 26 (20– 39) −2 (−8.9 to 2.5) <0.001
ALAT, U/L 27 (18– 45) −3 (−16 to 2) <0.001
HDL cholesterol, mmol/L 1.1 (0.9– 1.3) 0.04 (−0.08 to 
0.2)
0.053
LDL cholesterol, mmol/L 2.5 (2.0– 3.2) 0.1 (−0.5 to 0.4) 0.451
Total cholesterol, mmol/L 4.1 (3.4– 5.0) 0.1 (−0.3 to 0.7) 0.080
Renal function
Creatinine, µmol/L 98 (83– 122) 4 (−8 to 21) <0.001
 (Continued)
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points and 3 HDL functionality modalities to evalu-
ate the prognostic utility of measures of HDL func-
tion and adjusted for their respective BIOSTAT- CHF 
risk models. The assumption of proportionality of 
hazards and linearity were checked in all analyses. 
Results are expressed as hazard ratios with 95% CIs. 
The spline was constructed using the R packages 
Greg, rms, and splines. The correlation plot was con-
structed using the corrplot package. Additionally the 
R packages car, DescTools, foreign, ggplot2, ggpubr, 
Hmisc, lm.beta, psych, reshape2, sqldf, survival, and 
survminer were used in statistical analysis. A 2- tailed 
P- value <0.05 was considered statistically signifi-
cant. Statistical analyses were performed with SPSS 
Statistics version 23 (IBM, Armonk, NY) and R ver-
sion 3.4.3 (R Foundation for Statistical Computing, 
Vienna, Austria; www.r- proje ct.org).
RESULTS
Study Population Characteristics and HDL 
Functionality Over Time
Clinical characteristics of the study population at 
baseline and after 9 months (paired differences; ex-
cluding patients who died before the 9- month meas-
urement; n=383) are displayed in Table 1. Compared 
with baseline, at 9 months patients had less ad-
vanced HF (less often New York Heart Association 
class III/IV, lower NT- proBNP concentrations, and 
higher left ventricular ejection fraction), worse renal 
function (lower estimated glomerular filtration rate 
and a higher degree of tubular damage, as measured 
by plasma neutrophil gelatinase- associated lipocalin 
concentrations), and more often used angiotensin- 
converting enzyme inhibitors and beta blockers (all 
P<0.001). HDL, LDL, and total cholesterol concen-
trations and statin use did not significantly change. 
Clinical characteristics of the study population in-
cluding all patients at baseline (N=446) are shown in 
Table S3.
Measures of HDL functionality at baseline and 
after 9 months are displayed in Figure 1. HDL choles-
terol efflux had decreased after 9 months compared 
with baseline (baseline median, 5.8%; 9 months, 
4.6%; P<0.001). HDL anti- inflammatory capacity had 
also decreased (baseline median, 17.6% reduction; 
9 months, 15.2%; P<0.001), as expressed by less 
reduction of vascular cell adhesion molecule- 1 ex-
pression by HDL. In contrast, a greater reduction of 
thiobarbituric acid reactive substances accumula-
tion was observed, reflecting better antioxidative ca-
pacity of HDL (baseline median, 49.3% reduction; 9 
months, 53.3%; P<0.001). Unpaired differences are 
shown in Figure S1.
Compared with patients who were still alive at 9 
months, patients who died before the 9- month fol-
low- up measurement had worse baseline HDL cho-
lesterol efflux (5.3% versus 5.8%; P=0.005, after 
Bonferroni correction P=0.015), but had similar an-
tioxidative capacity (51.0% reduction versus 49.3%; 
P=0.439) and anti- inflammatory capacity (17.5% re-
duction versus 17.6% reduction; P=0.614).
There were no differences in HDL functionality 
and HDL cholesterol at baseline between patients 
with HF with reduced ejection fraction and HF with 
preserved ejection fraction (Figure S2), between pa-
tients with and without chronic kidney disease, and 
between patients with and without an ischemic eti-
ology of heart failure (data not shown). Measures 
of HDL functionality or their changes were also not 
associated with successful treatment optimization 
(data not shown). There were also no differences in 
HDL functionality between patients who used a sta-
tin and those who did not after applying Bonferroni 
correction.
Association Between HDL Functionality 
Measures and Clinical Variables
Correlation plots showing associations among the 3 
measures of HDL functionality are displayed in Figure 
S3. Baseline HDL cholesterol efflux significantly 
Baseline
Change From 
Baseline to 9 
Months P Value
eGFR, mL/min/1.73 m2 63±22 −4±16 <0.001
Urea, mmol/L 10.7 (7.3– 16.8) 0.2 (−1.9 to 2.7) 0.093
Plasma NGAL, ng/mL 53 (35– 81) 31 (5– 68) <0.001
Natriuretic peptides
NT- proBNP, pg/mL 3676 
(2185– 7059)
−983 (−3140 
to 85)
<0.001
BNP, pg/mL 222 (99– 447) −27 (−199 to 60) <0.001
ANP, ng/mL 20 (12– 39) 5 (−2 to 14) <0.001
Inflammatory markers
CRP, µg/mL 12.1 (4.8– 24.4) −6 (−18 to −2) <0.001
Myeloperoxidase, ng/mL 29 (23– 34) −0.03 (−5 to 5) 0.958
TNFR1A, ng/mL 1.0 (0.5– 1.5) 0.2 (−0.2 to 0.5) <0.001
N=383.
ACE indicates angiotensin- converting enzyme; ANP, atrial natriuretic 
peptide; ALAT, alanine aminotransferase; ARB, angiotensin receptor blocker; 
ASAT, aspartate aminotransferase; BNP, B- type natriuretic peptide; CRP, 
C- reactive protein; eGFR, estimated glomerular filtration rate; HDL, high- 
density lipoprotein; HFpEF, heart failure with preserved ejection fraction; 
LDL, low- density lipoprotein; LVEF, left ventricular ejection fraction; MRA, 
mineralocorticoid receptor antagonist; NGAL, neutrophil gelatinase- 
associated lipocalin; NT- proBNP, N- terminal pro- B- type natriuretic peptide; 
NYHA, New York Heart Association; and TNFR1A, tumor necrosis factor 
receptor 1 alfa.
*Paired differences; patients who died before the 9- month measurement 
were excluded.
†Based on target guideline- recommended treatment doses.25
Table 1. Continued
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
J Am Heart Assoc. 2021;10:e019123. DOI: 10.1161/JAHA.120.019123 6
Emmens et al High- Density Lipoprotein Function in Heart Failure
Figure 1. Differences in HDL functionality (relative to control) between 
baseline and 9 months.
Paired differences, N (patients) = 383. P values resulting from the Wilcoxon rank- 
sum test for paired samples. A, HDL cholesterol efflux at baseline (median, 5.8%) 
and 9 months (median, 4.6%), respectively; P<0.001. B, Antioxidative capacity 
at baseline (median, 49.3% reduction) and 9 months (median, 53.3% reduction), 
respectively; P<0.001. C, Anti- inflammatory capacity at baseline (median, 17.6% 
reduction) and 9 months (median, 15.2% reduction), respectively; P=0.046. D, HDL 
cholesterol concentration at baseline (median, 1.1 mmol/L) and 9 months (median, 
1.1 mmol/L), respectively; P=0.053. HDL indicates high- density lipoprotein.
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correlated with both baseline HDL antioxidative capac-
ity and anti- inflammatory capacity (Spearman’s rho = 
– 0.188, P<0.001; and 0.131, P=0.006, respectively). 
HDL antioxidative- capacity and anti- inflammatory ca-
pacity were not correlated with each other.
Tables S4 and S5 show determinants of HDL func-
tionality at baseline and at 9 months and changes of 
HDL functionality in univariable and multivariable re-
gression analysis, respectively. Change in HDL func-
tionality over time was, with respect to all 3 measures, 
most strongly determined by their respective baseline 
HDL functionality.
In regression analysis among statin users, rosuvas-
tatin use was associated with a greater reduction of 
anti- inflammatory capacity over time compared with 
other statins (standardized beta = – 0.155; t value, 
– 2.071; P=0.040). Statin dose was not associated with 
measures of HDL functionality.
HDL Cholesterol Efflux Is Associated With 
Mortality
In the current study population, 114 (26%) patients 
died, 115 (26%) were hospitalized for HF, and 183 (41%) 
either died or were hospitalized for HF during a me-
dian follow- up of 21 months. In Cox regression anal-
ysis (Table 2), higher baseline HDL cholesterol efflux 
was significantly associated with lower risk of all- cause 
mortality, which remained significant after adjustment 
for the previously described BIOSTAT- CHF risk model, 
enriched with age and log HDL cholesterol (hazard 
ratio, 0.81; 95% CI, 0.71– 0.92; P=0.001). However, HDL 
cholesterol efflux was not associated with HF hospitali-
zation and the composite end point. Hazard ratios on 
a continuum of HDL cholesterol efflux are displayed in 
Figure 2, demonstrating values on the lower end being 
associated with higher risk of mortality, and high values 
being associated with lower risk. HDL antioxidative ca-
pacity and anti- inflammatory capacity were not associ-
ated with clinical outcome, nor were changes of HDL 
functionality over time.
Correlations Between HDL Functionality 
and the HDL Proteome
In the HDL proteome cohort consisting of 86 patients 
with proteome data at baseline, median HDL cho-
lesterol efflux was 6.6% (5.3– 7.9), median HDL anti-
oxidative capacity was 44.0% (32.0– 51.8) reduction 
of TBARs, and median anti- inflammatory capacity 
was 32.0% (−2.0 to 55.8) reduction of vascular cell 
adhesion molecule- 1 expression by HDL at baseline. 
Figure 3 shows that several of the HDL proteins that 
were previously found to have the strongest asso-
ciation with outcome in this cohort were significantly 
correlated with HDL functionality. This applied par-
ticularly to apolipoprotein A1, which was the only 
protein from this set that was associated with all 3 
HDL functionality measures (rho=0.409, P<0.001 
for HDL cholesterol efflux; rho=−0.326, P=0.002 for 
anti- oxidative capacity; and rho=−0.282, P=0.009 for 
anti- inflammatory capacity). Others mainly correlated 
Figure 2. Hazard ratios for mortality on a continuum of HDL cholesterol efflux. N (patients) = 446.
The thick blue line represents the hazard ratio for mortality on a continuum of HDL cholesterol efflux 
with its corresponding 95% CI in lighter blue. In gray, the density of the population along the values of 
HDL cholesterol efflux is represented. The spline was truncated at the lower 5% and upper 5% of HDL 
cholesterol efflux. HDL indicates high- density lipoprotein.
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with HDL cholesterol efflux (alpha- 2- HS- glycoprotein, 
rho=0.269, P=0.012; apolipoprotein C3, rho=0.307, 
P=0.004; kallistatin, rho=0.326, P=0.002). HDL an-
tioxidative capacity was associated only with apoli-
poprotein A1, and anti- inflammatory capacity was 
additionally associated with kallistatin (rho=−0.325, 
P=0.002).
DISCUSSION
This study shows that HDL cholesterol efflux and 
anti- inflammatory capacity significantly decreased 
over time in patients with HF, whereas HDL anti-
oxidative capacity increased. HDL cholesterol efflux 
was independently associated with risk of all- cause 
mortality after adjustment for age, HDL cholesterol, 
and the developed risk model, which includes es-
tablished prognostic factors in HF, whereas anti- 
inflammatory and antioxidative capacity were not 
associated with clinical outcome. Finally, we show 
that certain proteins in the HDL proteome correlated 
with HDL functionality, with apolipoprotein A1 emerg-
ing as the main protein that was associated with all 
3 measures of HDL functionality. To the best of our 
knowledge, this is the first study to comprehensively 
investigate multiple measures of HDL functionality 
with serial measurements in a relatively large num-
ber of patients with HF, while furthermore linking HDL 
functionality to proteome composition.
From Studying HDL Cholesterol 
Concentrations to Studying HDL Quality 
in Heart Failure
Recently, low HDL cholesterol was found to be among 
the strongest predictors of death or HF hospitaliza-
tion in BIOSTAT- CHF,1 yet recent randomized con-
trolled trials have failed to show that increasing HDL 
cholesterol concentrations with niacin or cholesteryl 
ester transfer protein inhibitors reduces cardiovascu-
lar events.7 Beyond quantities of HDL cholesterol, a 
static measure, focus has therefore largely shifted to 
studying quality of HDL, a dynamic measure. These 
complex particles carry many different proteins (with 
>80 proteins consistently identified) in varying abun-
dances that are involved in many processes.26,27 HDL 
is a heterogenic lipoprotein; its composition and func-
tionality can be altered in various diseases, such as 
coronary artery disease and chronic kidney disease.8 
In experimental studies, HDL has shown to be cardio-
protective through its antioxidative, anti- inflammatory, 
antiapoptotic, and endothelial- protective effects.6 Only 
few smaller studies showed that in patients with HF 
HDL cholesterol efflux, antioxidative capacity, and anti- 
inflammatory capacity are reduced compared with 
controls,12,14 that HDL antioxidative capacity is a pre-
dictor of mortality,15 and that lower arylesterase activ-
ity (being used as a proxy integrating antioxidative and 
anti- inflammatory effects) was associated with adverse 
cardiac events.28,29
In the present study, including a larger number of 
patients, we showed that higher HDL cholesterol ef-
flux was independently associated with lower risk of 
mortality in HF. Since HDL cholesterol efflux was not 
associated with HF hospitalization, this relationship 
with mortality might be through non– HF- specific re-
lated mechanisms. Such reasoning is supported by 
the fact that HDL cholesterol efflux is also strongly 
associated with mortality in myocardial infarction 
and chronic coronary artery disease in the general 
population.23,30– 32 However, other measures of HDL 
functionality were not associated with outcome in our 
study. HDL is involved with all stages of reverse cho-
lesterol transport with cholesterol efflux representing 
the first and arguably the most important step, pos-
sibly making this a central metric of overall HDL func-
tion.27 Mechanisms of HDL in reducing antioxidative 
stress and inflammation are furthermore complex and 
Table 2. Cox Regression of HDL Cholesterol Efflux and Outcome
Variable
Univariable
Corrected for Age + Log HDL 
Cholesterol
Corrected for Previous + BIOSTAT- 
CHF Risk Model†
HR* (95% CI) P Value HR* (95% CI) P Value HR* (95% CI) P Value
Mortality 0.88 (0.81– 0.95) 0.002 0.84 (0.74 – 0.95) 0.005 0.81 (0.71– 0.92) 0.001
HF hospitalization 0.99 (0.92– 1.06) 0.690
Mortality or HF 
hospitalization
0.95 (0.89– 1.00) 0.068
All- cause mortality: age, log blood urea nitrogen, log NT- proBNP, hemoglobin, and beta- blocker use at baseline.
HF hospitalization: age, HF hospitalization in previous year, peripheral edema, systolic blood pressure, and eGFR.
Combined endpoint: age, HF hospitalization in previous year, systolic blood pressure, log NT- proBNP, hemoglobin, high- density lipoprotein, sodium, and 
beta- blocker use at baseline.
BIOSTAT- CHF, A Systems Biology Study to Tailored Treatment in Chronic Heart Failure; HDL, high- density lipoprotein; HF, heart failure; HR, hazard ratio; 
NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*Reported as per unit increase of HDL cholesterol efflux (%).
†Variables in BIOSTAT- CHF risk score.
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remain incompletely understood. Anti- inflammatory 
and antioxidative effects have been shown to have 
a significant impact in inflammatory and autoimmune 
disorders and are partly directed toward atheropro-
tection (such as decreasing plaque inflammation)27; 
therefore the magnitude of effects might not be big 
enough in this mixed HF population. The discrepancy 
between the present study and previous studies that 
mostly did show a relationship between those mea-
sures and outcome might be found in the use of dif-
ferent methods to assess HDL functionality, the use 
of paraoxonase- 1 arylesterase activity as a surrogate 
measure for HDL functionality (with inconsistent re-
sults13,28,29), and different study populations (such as 
acute/chronic HF, severity of HF, and symptomatic/
asymptomatic).
Changes of HDL functionality over time were fur-
thermore not associated with outcome, suggesting 
that functionality at baseline already determines the 
prognostic risk with no incremental value from re-
peated measurements. HDL functionality might de-
velop into a “state of no return” once new- onset or 
worsening of HF has occurred, even though the gen-
eral condition and laboratory parameters of these pa-
tients improve after treatment. In contrast, antioxidative 
capacity of HDL increased over time, which is conceiv-
ably a counterregulatory effect of HDL in response to 
systemic oxidative stress. Similar observations have 
Figure 3. Correlation plot of HDL functionality measures and proteins of the HDL proteome. N 
(patients) = 86.
Correlation plot where the size and color of the dots represent the magnitude and direction of the 
association. Dark blue represents a strong positive correlation, whereas dark red represents a strong 
negative correlation. AHSG, Alpha- 2- HS- glycoprotein; ApoA1, apolipoprotein A1; ApoA2, apolipoprotein 
A2; ApoC3, apolipoprotein C3; B2M, beta- 2- microglobulin; Factor X, coagulation factor X; HDL, high- 
density lipoprotein; PSAP, pulmonary surfactant- associated protein B; PON1, serum paraoxonase/
arylesterase 1.
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previously been made, for example, with increased an-
tioxidative responses mounted in smokers.33 Changes 
of HDL functionality were very similar when all patients 
were included at baseline compared with paired differ-
ences, confirming that these findings apply regardless 
of prognosis.
Finally, HDL functionality has been proposed to be 
affected or important in certain subgroups of interest; 
clear disturbances have been observed of HDL func-
tionality in patients with chronic kidney disease,34 and 
the influence of HDL functionality might be greater in 
HF with preserved ejection fraction compared with HF 
with reduced ejection fraction attributable to the effects 
HDL exerts on cardiovascular comorbidities, such as 
hypertension and diabetes mellitus.6 However, we did 
not observe a difference in HDL functionality between 
presence and absence of these 2 conditions, keeping 
in mind the low number of patients with HF with pre-
served ejection fraction. Furthermore, the influence of 
statin use and dose on HDL functionality appeared to 
be little.
The Relationship Between HDL Proteome 
and Functionality
In an earlier follow- up study with the aim of finding an 
explanation for the association between low HDL cho-
lesterol and worse outcomes in patients with HF, we 
showed that HDL proteome composition is markedly 
different between patients with HF with poor survival 
compared with those with relatively better survival.11 In 
this study, we established 12 proteins that were con-
sistently reported as being part of the HDL proteome 
and were most strongly associated with outcome, 
validated using different search techniques.11 To our 
knowledge, only 1 study investigated both HDL pro-
teome composition and NO- related activities of HDL 
as a readout of HDL functionality in a rather limited 
number of patients with HF but did not provide a direct 
comparison.35
Apolipoprotein A1 seems to be the best reflector 
of HDL functionality as a whole, with strongest ties to 
cholesterol efflux. Apolipoprotein A1 is the major struc-
tural and functional component of HDL, which is be-
lieved to be present in almost all HDL particles, and 
accounts for ≈70% of total HDL protein content.36 It 
is well established that apolipoprotein A1 is involved 
in promoting efflux (confirmed with a positive associ-
ation in correlation analysis) and can also act as an 
antioxidative and anti- inflammatory agent.27 In line with 
this, apolipoprotein A1 has also already been shown 
to be associated with arylesterase activity29 and ad-
verse outcome in previous HF studies,4,11 also to a 
larger extent than LDL cholesterol or HDL cholesterol.5 
However, as mentioned before, antioxidative and anti- 
inflammatory function are complex processes not 
solely determined by apolipoprotein A1 but exerted by 
multiple proteins within the proteome, which might ex-
plain the somewhat unexpected finding that apolipo-
protein A1 was negatively associated with antioxidative 
and anti- inflammatory function. An advantage of apoli-
poprotein A1 is the fact that it is easier to measure than 
(separate) modalities of HDL functionality, which are 
thus far still largely reserved for experimental settings, 
and is therefore more clinically applicable. However, 
apolipoprotein A1 is also present on chylomicrons and 
very- low- density lipoproteins, making it not uniquely 
HDL associated.36
Strengths and Limitations
First, we were able to investigate HDL functionality in 
relation to a large array of different clinical variables 
and biomarkers in a sizeable subset of this multicenter, 
multinational, and heterogeneous HF population, 
which is a strength of our study. The heterogeneous 
nature of the study population also renders the results 
more easily applicable to the general HF population. 
Furthermore, we included 3 measures of HDL func-
tionality with well- established methodology and de-
tailed, high- quality data on HDL proteome composition 
all in 1 comprehensive study.
However, we were formally not able to show cau-
sality because of the retrospective nature of this 
study. No validation of results in an independent co-
hort is also a limitation of our study. Some analyses 
included fewer patients because of missing values. 
Furthermore, from a technical perspective, we feel 
that it is important to point out that there is no estab-
lished gold standard of measuring HDL functionality. 
This includes the methods for HDL isolation as well as 
the respective assay conditions. For example, isolat-
ing HDL by precipitating apolipoprotein B– containing 
lipoproteins is feasible for the study of larger co-
horts,12,22,24,30– 32 preserves the HDL proteome, and 
captures pre- beta HDL particles. However, cer-
tain plasma components other than HDL remain in 
these preparations. In contrast, with an ultracen-
trifugation method, a somewhat purer HDL prepa-
ration could be obtained on the expense of losing 
HDL- associated proteins as well as pre- beta HDL 
particles because of the centrifugal forces applied 
and the cutoffs handled. Further, longer centrifuga-
tion protocols using higher temperatures can result 
in additional alterations of HDL particles.9 Therefore, 
HDL function assays, although, as in our study, well 
standardized within the laboratory, are not compa-
rable to the measurement of parameters in routine 
clinical chemistry laboratories and need to be judged 
in the context of the HDL isolation method and the 
assay conditions applied. This complicates compar-
ison between studies from different groups. Finally, 
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the measurements were performed in a subset of 
patients, and even though no substantial differences 
were observed between included and excluded pa-
tients, informed censoring cannot be fully ruled out.
Clinical Relevance and Future 
Perspectives
We have studied HDL functionality to a detailed extent 
in HF and also directly linked HDL functionality to HDL 
proteome composition. We found that HDL choles-
terol efflux might be a clinically relevant target aspect 
of HDL functionality for therapeutic intervention. Future 
studies should confirm whether HDL cholesterol ef-
flux is a causal factor, but evidence so far appears 
compelling. In future studies, it will also be interesting 
to address the potential of recombinant HDL, which 
has been shown to favorably alter HDL metabolism.7 
Additionally, one small study showed that the ability 
of HDL to stimulate endothelial NO production could 
be partially restored with exercise training in advanced 
HF,35 also representing an interesting way to possibly 
increase functionality of HDL, along with the many 
other benefits of exercise training. Finally, in addition 
to studying HDL content and functionality, focusing 
on subfractions of HDL particles also appears to be 
promising, with smaller particles being more favorably 
associated with outcome and better functionality than 
less dense particles. This has recently been reported 
in the largest HF population to date, including both re-
duced and preserved ejection fraction.37
CONCLUSIONS
Better HDL cholesterol efflux at baseline was associ-
ated with a lower risk of mortality during follow- up in-
dependent of HDL cholesterol. HDL cholesterol efflux 
and anti- inflammatory capacity declined during follow-
 up in patients with HF, possibly signifying a “state of 
no return” for HDL functionality. Combined, these data 
indicate that measures of HDL function may provide 
clinical information beyond static HDL cholesterol 
concentration in patients with HF. Apolipoprotein A1 
emerged as an important protein that is associated 
with all 3 measures of HDL functionality.
ARTICLE INFORMATION
Received October 20, 2020; accepted March 1, 2021.
Affiliations
Department of Cardiology (J.E.E., D.J.v.V., A.A.V., R.A.d.B.); and Department 
of Pediatrics (C.J., U.J.T.), University of Groningen, Groningen, The 
Netherlands; ; Division of Clinical Chemistry, Department of Laboratory 
Medicine, Karolinska Institutet, Stockholm, Sweden (C.J., U.J.T.); ; 
Department of Cardiovascular Sciences, Glenfield Hospital, University of 
Leicester, Leicester, UK (L.L.N.); ; NIHR Leicester Biomedical Research 
Centre, Leicester, UK (L.L.N.); ; University of Bergen, Bergen, Norway (K.D.); 
; Stavanger University Hospital, Stavanger, Norway (K.D.); ; Department 
of Cardiology (CVK), Berlin, Germany (S.D.A.); Berlin- Brandenburg Center 
for Regenerative Therapies (BCRT), Berlin, Germany (S.D.A.); German 
Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité 
Universitätsmedizin Berlin, Berlin, Germany (S.D.A.); Department of 
Cardiology and Pneumology, University Medical Center Göttingen (UMG), 
Göttingen, Germany (S.D.A.); School of Medicine Centre for Cardiovascular 
and Lung Biology, Division of Molecular and Clinical Medicine, University 
of Dundee, Dundee, UK (C.C.L.); National and Kapodistrian University of 
Athens, School of Medicine, Athens, Greece (G.F.); University of Cyprus, 
School of Medicine, Nicosia, Cyprus (G.F.); National Heart & Lung Institute, 
Royal Brompton & Harefield Hospitals, Imperial College, London, UK 
(J.G.C.); Robertson Institute of Biostatistics and Clinical Trials Unit, University 
of Glasgow, Glasgow, UK (J.G.C.); Institute of Cardiology, Department of 
Medical and Surgical Specialties, Radiological Sciences and Public Health, 
University of Brescia, Brescia, Italy (M.M.); and Clinical Chemistry, Karolinska 
University Laboratory, Karolinska University Hospital, Stockholm, SE- 141 86, 
Sweden (U.J.T.).
Sources of Funding
This work was supported by the European Commission [FP7- 242209- 
BIOSTAT- CHF; EudraCT 2010- 020808- 29].
Disclosures
Dr Jia was supported by a fellowship from the Chinese Scholarship Council. 
SDA reports receiving fees from Bayer, Boehringer Ingelheim, Cardiac 
Dimension, Impulse Dynamics, Novartis, Servier, St. Jude Medical, and 
Vifor Pharma; and grant support from Abbott Vascular and Vifor Pharma. 
Dr Lang received consultancy fees or research grants from Amgen, Applied 
Therapeutics, Astra Zenenca, Boehringher Ingelheim, MSD, and Novartis. 
Dr Filippatos participated in committees of trials and registries sponsored 
by Novartis, Servier, Bayer, BI, Vifor, and Medtronic. Dr Voors received 
consultancy fees or research grants from Amgen, Applied Therapeutics, 
AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GSK, Merck, 
Myokardia, Novartis, Roche Diagnostics, and Servier. Dr de Boer received 
speaker fees from Abbott, AstraZeneca, Novartis, and Roche. Dr Tietge re-
ceived consultancy fees from AstraZeneca. The University Medical Center 
Groningen, which employs several of the authors, has received research 
grants or fees from AstraZeneca, Abbott, Bristol- Myers Squibb, Novartis, 
Novo Nordisk, and Roche. The remaining authors have no disclosures to 
report.
Supplementary Material
Tables S1– S5
Figures S1– S3
REFERENCES
 1. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani 
NJ, Ponikowski P, Ng LL, Metra M, Ter Maaten JM, Lang CC, et al. 
Development and validation of multivariable models to predict mortal-
ity and hospitalization in patients with heart failure. Eur J Heart Fail. 
2017;19:627– 634. DOI: 10.1002/ejhf.785.
 2. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy 
D. Relations of lipid concentrations to heart failure incidence: the 
Framingham Heart Study. Circulation. 2009;120:2345– 2351. DOI: 
10.1161/CIRCU LATIO NAHA.109.830984.
 3. Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High- 
density lipoprotein cholesterol levels and prognosis in advanced heart 
failure. J Heart Lung Transplant. 2009;28:876– 880. DOI: 10.1016/j.
healun.2009.04.026.
 4. Iwaoka M, Obata J, Abe M, Nakamura T, Kitta Y, Kodama Y, Kawabata 
K, Takano H, Fujioka D, Saito Y, et al. Association of low serum levels 
of apolipoprotein A- I with adverse outcomes in patients with nonisch-
emic heart failure. J Card Fail. 2007;13:247– 253. DOI: 10.1016/j.cardf 
ail.2007.01.007.
 5. Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel 
JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, et al. Study 
Group. Predictors of fatal and non- fatal outcomes in the Controlled 
Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental 
value of apolipoprotein A- 1, high- sensitivity C- reactive peptide and N- 
terminal pro B- type natriuretic peptide. Eur J Heart Fail. 2009;11:281– 
291. DOI: 10.1093/eurjh f/hfn046.
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
J Am Heart Assoc. 2021;10:e019123. DOI: 10.1161/JAHA.120.019123 12
Emmens et al High- Density Lipoprotein Function in Heart Failure
 6. Van Linthout S, Frias M, Singh N, De Geest B. Therapeutic potential 
of HDL in cardioprotection and tissue repair. Handb Exp Pharmacol. 
2015;224:527– 565. DOI: 10.1007/978- 3- 319- 09665 - 0_17.
 7. Rader DJ. New therapeutic approaches to the treatment of dyslipid-
emia. Cell Metab. 2016;23:405– 412. DOI: 10.1016/j.cmet.2016.01.005.
 8. Constantinou C, Karavia EA, Xepapadaki E, Petropoulou P- I, Papakosta 
E, Karavyraki M, Zvintzou E, Theodoropoulos V, Filou S, Hatziri A, et al. 
Advances in high- density lipoprotein physiology: surprises, overturns, 
and promises. Am J Physiol Endocrinol Metab. 2016;310:E1– E14. DOI: 
10.1152/ajpen do.00429.2015.
 9. Triolo M, Annema W, Dullaart RPF, Tietge UJF. Assessing the func-
tional properties of high- density lipoproteins: an emerging concept in 
cardiovascular research. Biomark. Med. 2013;7:457– 472. DOI: 10.2217/
bmm.13.35.
 10. Mentz RJ, O’Connor CM. Pathophysiology and clinical evaluation of 
acute heart failure. Nat Rev Cardiol. 2015;13:28– 35. DOI: 10.1038/nrcar 
dio.2015.134.
 11. Emmens JE, Jones DJL, Cao TH, Chan DCS, Romaine SPR, Quinn 
PA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Proteomic 
diversity of high- density lipoprotein explains its association with clinical 
outcome in patients with heart failure. Eur J Heart Fail. 2018;20:260– 
267. DOI: 10.1002/ejhf.1101.
 12. Patel PJ, Khera AV, Wilensky RL, Rader DJ. Anti- Oxidative and cho-
lesterol efflux capacities of high- density lipoprotein are reduced in 
ischaemic cardiomyopathy. Eur J Heart Fail. 2013;15:1215– 1219. DOI: 
10.1093/eurjh f/hft084.
 13. Potočnjak I, Degoricija V, Trbušić M, Terešak SD, Radulović B, Pregartner 
G, Berghold A, Tiran B, Marsche G, Frank S. Metrics of high- density li-
poprotein function and hospital mortality in acute heart failure patients. 
PLoS One. 2016;11:e0157507. DOI: 10.1371/journ al.pone.0157507.
 14. Kim JB, Hama S, Hough G, Navab M, Fogelman AM, MacLellan WR, 
Horwich TB, Fonarow GC. Heart failure is associated with impaired anti- 
inflammatory and antioxidant properties of high- density lipoproteins. 
Am J Cardiol. 2013;112:1770– 1777. DOI: 10.1016/j.amjca rd.2013.07.045.
 15. Schrutka L, Distelmaier K, Hohensinner P, Sulzgruber P, Lang IM, 
Maurer G, Wojta J, Hülsmann M, Niessner A, Koller L. Impaired high- 
density lipoprotein anti- oxidative function is associated with outcome in 
patients with chronic heart failure. J Am Heart Assoc. 2016;5:e004169. 
DOI: 10.1161/JAHA.116.004169.
 16. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der 
Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, et al. A systems 
BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, 
design, and baseline characteristics of BIOSTAT- CHF. Eur J Heart Fail. 
2016;18:716– 726. DOI: 10.1002/ejhf.531.
 17. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos 
G, van der Harst P, Hillege HL, Lang CC, ter Maaten JM, et al. 
Determinants and clinical outcome of uptitration of ACE- inhibitors and 
beta- blockers in patients with heart failure: a prospective European 
study. Eur Heart J. 2017;38:1883– 1890. DOI: 10.1093/eurhe artj/ehx026.
 18. Ronsein GE, Vaisar T. Deepening our understanding of HDL pro-
teome. Expert Rev Proteomics. 2019;16:749– 760. DOI: 10.1080/14789 
450.2019.1650645.
 19. Helfand M, Carson S, Kelley C. Drug Class Review on HMG- CoA 
Reductase Inhibitors (Statins). Final Report [Internet]. 2006.
 20. ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, 
Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, et 
al. Fibroblast growth factor 23 is related to profiles indicating volume 
overload, poor therapy optimization and prognosis in patients with new- 
onset and worsening heart failure. Int J Cardiol. 2018;253:84– 90. DOI: 
10.1016/j.ijcard.2017.10.010.
 21. Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, 
Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, et 
al. Biomarker- guided versus guideline- based treatment of patients 
with heart failure: results from BIOSTAT- CHF. J Am Coll Cardiol. 
2018;71:386– 398. DOI: 10.1016/j.jacc.2017.11.041.
 22. Kopecky C, Ebtehaj S, Genser B, Drechsler C, Krane V, Antlanger M, 
Kovarik JJ, Kaltenecker CC, Parvizi M, Wanner C, et al. HDL cholesterol 
efflux does not predict cardiovascular risk in hemodialysis patients. 
J Am Soc Nephrol. 2017;28:769– 775. DOI: 10.1681/ASN.20160 30262.
 23. Ebtehaj S, Gruppen EG, Bakker SJL, Dullaart RPF, Tietge UJF. HDL 
(high- density lipoprotein) cholesterol efflux capacity is associated with 
incident cardiovascular disease in the general population. Arterioscler 
Thromb Vasc Biol. 2019;39:1874– 1883. DOI: 10.1161/ATVBA 
HA.119.312645.
 24. Annema W, Willemsen HM, de Boer JF, Dikkers A, van der Giet M, 
Nieuwland W, Muller Kobold AC, van Pelt LJ, Slart RHJA, van der Horst 
ICC, et al. HDL function is impaired in acute myocardial infarction inde-
pendent of plasma HDL cholesterol levels. J Clin Lipidol. 2016;10:1318– 
1328. DOI: 10.1016/j.jacl.2016.08.003.
 25. Dickstein K, Cohen- Solal A, Filippatos G, McMurray JJV, Ponikowski P, 
Poole- Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, 
et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for 
the diagnosis and treatment of acute and chronic heart failure 2008: 
the Task Force for the Diagnosis and Treatment of Acute and Chronic 
Heart Failure 2008 of the European Society of Cardiology. Developed 
in collaboration with the Heart Failure Association of the ESC (HFA) and 
endorsed by the European Society of Intensive Care Medicine (ESICM). 
Eur J Heart Fail. 2008;10:933– 989. DOI: 10.1016/j.ejhea rt.2008.08.005.
 26. Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high 
density lipoproteins: our emerging understanding of its importance 
in lipid transport and beyond. J Lipid Res. 2013;54:2575– 2585. DOI: 
10.1194/jlr.R035725.
 27. von Eckardstein A, Kardassis D. High density lipoproteins: from bio-
logical understanding to clinical exploitation. Handb Exp Pharmacol. 
2015;224:1– 565. DOI: 10.1007/978- 3- 319- 09665 - 0.
 28. Tang WHW, Wu Y, Mann S, Pepoy M, Shrestha K, Borowski AG, 
Hazen SL. Diminished antioxidant activity of high- density lipoprotein- 
associated proteins in systolic heart failure. Circ Heart Fail. 2011;4:59– 
64. DOI: 10.1161/CIRCH EARTF AILURE.110.958348.
 29. Hammadah M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, Wu 
Y, Hazen SL, Butler J, Tang WHW. High- density lipoprotein- associated 
paraoxonase- 1 activity for prediction of adverse outcomes in outpa-
tients with chronic heart failure. Eur J Heart Fail. 2017;19:748– 755. DOI: 
10.1002/ejhf.777.
 30. Khera AV, Cuchel M, De La Llera- Moya M, Rodrigues A, Burke MF, 
Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al. 
Cholesterol efflux capacity, high- density lipoprotein function, and ath-
erosclerosis. N Engl J Med. 2011;364:127– 135. DOI: 10.1056/NEJMo 
a1001689.
 31. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, 
Neeland IJ, Yuhanna IS, Rader DR, De Lemos JA, et al. HDL choles-
terol efflux capacity and incident cardiovascular events. N Engl J Med. 
2014;371:2383– 2393. DOI: 10.1056/NEJMo a1409065.
 32. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, 
Lukmanova D, Mucksavage ML, Luben R, Billheimer J, et al. Association 
of HDL cholesterol efflux capacity with incident coronary heart disease 
events: a prospective case- control study. Lancet Diabetes Endocrinol. 
2015;3:507– 513. DOI: 10.1016/S2213 - 8587(15)00126 - 6.
 33. Charalabopoulos K, Assimakopoulos D, Karkabounas S, Danielidis V, 
Kiortsis D, Evangelou A. Effects of cigarette smoking on the antioxidant 
defence in young healthy male volunteers. Int J Clin Pract. 2005;59:25– 
30. DOI: 10.1111/j.1742- 1241.2004.00340.x.
 34. Kronenberg F. HDL in CKD- the devil is in the detail. J Am Soc Nephrol. 
2018;29:1356– 1371. DOI: 10.1681/ASN.20170 70798.
 35. Adams V, Besler C, Fischer T, Riwanto M, Noack F, Höllriegel R, 
Oberbach A, Jehmlich N, Völker U, Winzer EB, et al. Exercise training in 
patients with chronic heart failure promotes restoration of high- density 
lipoprotein functional properties. Circ Res. 2013;113:1345– 1355. DOI: 
10.1161/CIRCR ESAHA.113.301684.
 36. Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson 
WS. Structure of HDL: particle subclasses and molecular components. 
Handb Exp Pharmacol. 2015;224:3– 51. DOI: 10.1007/978- 3- 319- 09665 
- 0_1.
 37. Hunter WG, McGarrah RW, Kelly JP, Khouri MG, Craig DM, Haynes 
C, Felker GM, Hernandez AF, Velazquez EJ, Kraus WE, et al. High- 
density lipoprotein particle subfractions in heart failure with preserved 
or reduced ejection fraction. J Am Coll Cardiol. 2019;73:177– 186. DOI: 
10.1016/j.jacc.2018.10.059.
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
 
 
 
Supplemental Material 
 
  
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
Table S1. Comparison of baseline characteristics between present study cohort and patients 
not in study subset.  
Variable HDL functionality 
cohort (N = 446) 
Patients without HDL 
functionality 
measurements (N = 2,070)  
P-value 
Clinical variables 
Age (years) 69 ± 12 69 ± 12 0.880 
Sex (male), n (%) 323 (72) 1523 (74) 0.659 
NYHA classification 
(III/IV), n (%) 
246 (55) 1276 (62) 0.015 
Systolic blood 
pressure (mmHg) 
123 ± 21 125 ± 22 0.020 
Diastolic blood 
pressure (mmHg) 
74 ± 13 75 ± 13 0.062 
Heart rate (bpm) 81 ± 21 80 ± 19 0.122 
LVEF (%) 30 (24 – 35) 30 (25 – 37) 0.475 
HFpEF/LVEF>45%, n 
(%) 
31 (7) 131 (6) 0.616 
Diabetes mellitus, n 
(%) 
125 (28) 694 (34) 0.028 
Smoking (past or 
current), n (%) 
282 (63) 1291 (62) 0.686 
Primary heart failure etiology, n (%) 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
Ischemic heart 
disease 
194 (43) 932 (45) 0.747 
Hypertension 45 (10) 211 (10) 0.877 
Cardiomyopathy 104 (23) 527 (25) 0.592 
Valvular disease 37 (8) 153 (7) 0.690 
Medication, n (%) 
ACE inhibitor/ARB 328 (74) 1492 (72) 0.569 
Beta-blocker 373 (84) 1720 (83) 0.836 
Loop diuretics 445 (99) 2059 (99) 0.635 
MRA 233 (52) 1106 (53) 0.686 
Laboratory values 
Hemoglobin (g/dL) 13.3 ± 1.9 13.2 ± 1.9 0.291 
Sodium (mmol/L) 140 (137 – 142) 140 (137 – 142) 0.763 
Potassium (mmol/L) 4.2 (3.9 – 4.5) 4.2 (3.9 – 4.6) 0.354 
ASAT (U/L) 27 (20 – 39) 25 (19 – 34) 0.025 
ALAT (U/L) 26 (18 – 44) 25 (16 – 37) 0.043 
HDL cholesterol 
(mmol/L) 
1.1 (0.8 – 1.3) 1.0 (0.8 – 1.3) 0.653 
LDL-cholesterol 
(mmol/L) 
2.4 (1.8 – 3.2) 2.4 (1.8 – 3.2) 0.945 
Total cholesterol 
(mmol/L) 
4.0 (3.3 – 5.0) 4.1 (3.3 – 5.0) 0.583 
Renal function 
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Creatinine (µmol/L) 99 (85 – 126) 103 (84 – 132) 0.440 
eGFR 
(mL/min/1.73m2) 
61 ± 23 60 ± 23 0.608 
Urea (mmol/L) 11.2 (7.6 – 17.2) 11.4 (7.6 – 18.6) 0.373 
Natriuretic peptides 
NT-proBNP (pg/mL) 3915 (2330 – 7391) 4342 (2373 – 8648) 0.256 
BNP (pg/mL) 259 (106 – 505) 225 (89 – 465) 0.069 
Event rates, n (%) 
Mortality 114 (26) 554 (27) 0.644 
- Days to 
event 
646 (487 – 831) 645 (468 – 819) 0.263 
HF hospitalization 115 (26) 507 (24) 0.608 
- Days to 
event 
564 (275 – 798) 550 (251 – 774) 0.359 
Combined endpoint 183 (41) 850 (41) 1 
- Days to 
event 
564 (275 – 798) 550 (251 – 774) 0.359 
 
ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARB, angiotensin 
receptor blocker; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; CRP, C-
reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
HFpEF, heart failure with preserved ejection fraction; LDL, low-density lipoprotein; LVEF, left 
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N 
terminal pro brain natriuretic peptide; NYHA, New York Heart Association 
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Table S2. Baseline characteristics of the HDL proteome cohort including differences between 
this cohort and the HDL functionality cohort and BIOSTAT-CHF patients not in the proteome 
cohort 
 
Variable HDL 
proteome 
cohort* 
(n=86) 
HDL 
functionality 
cohort 
(n=446) 
P-value† BIOSTAT-
CHF 
patients 
not 
included in 
HDL 
proteome 
cohort 
(n=2,430) 
P-value‡ 
Clinical variables 
Age (years) 70 ± 9 69 ± 12 0.241 69 ± 12 0.200 
Sex (male), n (%) 75 (87) 323 (72) 0.006 1771 (73) 0.005 
NYHA 
classification 
(III/IV), n (%) 
30 (35) 246 (55) <0.001 1452 (60) <0.001 
Systolic blood 
pressure (mmHg) 
121 ± 23 123 ± 21 0.648 125 ± 22 0.172 
Diastolic blood 
pressure (mmHg) 
73 ± 13 74 ± 13 0.541 75 ± 13 0.143 
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Heart rate (bpm) 78 ± 17 81 ± 21 0.078 80 ± 20 0.200 
LVEF (%) 28 (21 – 30) 30 (24 – 35) 0.004 30 (25 – 
37) 
<0.001 
HFpEF/LVEF>45%, 
n (%) 
0 (0) 31 (7) 0.014 162 (7) 0.015 
Diabetes mellitus, 
n (%) 
38 (44) 125 (28) 0.004 781 (32) 0.026 
Smoking (past or 
current), n (%) 
66 (77) 282 (63) 0.020 1507 (62) 0.010 
Primary heart failure etiology, n (%) 
Ischemic heart 
disease 
86 (100) 194 (43) <0.001 1040 (43) <0.001 
Hypertension 0 (0) 45 (10) 0.036 255 (10) 0.020 
Cardiomyopathy 0 (0) 104 (23) <0.001 630 (26) <0.001 
Valvular disease 0 (0) 37 (8) 0.045 189 (8) 0.028 
Medication, n (%) 
ACE inhibitor/ARB 59 (69) 328 (74) 0.418 1761 (72) 0.506 
Beta-blocker 71 (83) 373 (84) 0.931 2022 (83) 0.990 
Loop diuretics 86 (100) 445 (99) 1 2418 (100) 1 
MRA 51 (59) 233 (52) 0.279 1288 (53) 0.298 
Laboratory values 
Hemoglobin 
(g/dL) 
13.1 ± 1.6 13.3 ± 1.9 0.013 13.2 ± 1.9 0.019 
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Sodium (mmol/L) 139 (136 – 
141) 
140 (137 – 
142) 
0.083 140 (137 – 
142) 
0.073 
Potassium 
(mmol/L) 
4.2 (4.0 – 
4.7) 
4.2 (3.9 – 4.5) 0.585 4.2 (3.9 – 
4.6) 
0.774 
ASAT (U/L) 24 (17 – 34) 27 (20 – 39) 0.035 25 (19 – 
35) 
0.134 
ALAT (U/L) 22 (15 – 33) 26 (18 – 44) 0.024 25 (17 – 
38) 
0.083 
HDL cholesterol 
(mmol/L) 
1.0 (0.7 – 
1.3) 
1.1 (0.8 – 1.3) 0.121 1.1 (0.9 – 
1.3) 
0.129 
LDL-cholesterol 
(mmol/L) 
2.1 (1.7 – 
2.8) 
2.4 (1.8 – 3.2) 0.085 2.5 (1.8 – 
3.2) 
0.060 
Total cholesterol 
(mmol/L) 
3.5 (3.1 – 
4.4) 
4.0 (3.3 – 5.0) 0.020 4.1 (3.4 – 
5.0) 
0.006 
Renal function 
Creatinine 
(µmol/L) 
115 (100 – 
150) 
99 (85 – 126) <0.001 102 (83 – 
129) 
<0.001 
eGFR 
(mL/min/1.73m2) 
52 ± 19 61 ± 23 <0.001 61 ± 23 <0.001 
Urea (mmol/L) 19.6 (11.7 – 
28.4) 
11.2 (7.6 – 
17.2) 
<0.001 11.2 (7.5 – 
17.9) 
<0.001 
Natriuretic peptides 
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NT-proBNP 
(pg/mL) 
6920 (3447 
– 11119) 
3915 (2330 – 
7391) 
0.022 4226 
(2358 – 
8325) 
0.033 
BNP (pg/mL) 423 (207 – 
694) 
259 (106 – 
505) 
<0.001 224 (92 – 
462) 
<0.001 
 
* Patients of the HDL proteome cohort were selected from BIOSTAT-CHF based on the 
characteristics that they could be matched with a 1:1 death/survivor ratio of cardiovascular 
cause within a follow-up period of 12 months. Patients were furthermore matched for 
important prognostic criteria. Therefore, there are inherent differences between this cohort 
and the overall BIOSTAT-CHF cohort and the HDL functionality cohort. Detailed methodology 
on the selection procedure has been published previously.11 
†Comparison between HDL proteome cohort and HDL functionality cohort 
‡Comparison between HDL proteome cohort and BIOSTAT-CHF patients not included in HDL 
proteome cohort 
ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARB, angiotensin 
receptor blocker; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; CRP, C-
reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
HFpEF, heart failure with preserved ejection fraction; LDL, low-density lipoprotein; LVEF, left 
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N 
terminal pro brain natriuretic peptide; NYHA, New York Heart Association 
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Table S3. Baseline characteristics of the HDL functionality cohort at baseline* 
Clinical characteristics 
Age (years) 69 ± 12 
Sex (male), n (%) 323 (72) 
NYHA classification (III/IV), n (%) 246 (55) 
Systolic blood pressure (mmHg) 123 ± 21 
Diastolic blood pressure (mmHg) 74 ± 13 
Heart rate (bpm) 81 ± 21 
LVEF (%) 30 (24 – 35) 
HFpEF/LVEF>45%, n (%) 31 (7) 
Diabetes mellitus, n (%) 125 (28) 
Smoking (past or current), n (%) 282 (63) 
Primary heart failure etiology, n (%) 
Ischemic heart disease 194 (43) 
Hypertension 45 (10) 
Cardiomyopathy 104 (23) 
Valvular disease 37 (8) 
Medication, n (%) 
ACE inhibitor/ARB 328 (74) 
- 50% target dose† 177 (40) 
- 100% target dose† 59 (13) 
Beta-blocker 373 (84) 
- 50% target dose† 127 (28) 
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- 100% target dose† 21 (5) 
Loop diuretics 445 (99) 
MRA 233 (52) 
Statins (total) 229 (51) 
- Simvastatin 98 (43) 
- Atorvastatin 91 (40) 
- Rosuvastatin 21 (9) 
- Pravastatin 17 (7) 
- Fluvastatin 2 (0) 
Laboratory values 
Hemoglobin (g/dL) 13.3 ± 1.9 
Sodium (mmol/L) 140 (137 – 142) 
Potassium (mmol/L) 4.2 (3.9 – 4.5) 
ASAT (U/L) 27 (20 – 39) 
ALAT (U/L) 26 (18 – 44) 
HDL cholesterol (mmol/L) 1.1 (0.8 – 1.3) 
LDL cholesterol (mmol/L) 2.4 (1.8 – 3.2) 
Total cholesterol (mmol/L) 4.0 (3.3 – 5.0) 
Renal function 
Creatinine (µmol/L) 99 (85 – 126) 
eGFR (mL/min/1.73m2) 61 ± 23 
Urea (mmol/L) 11.2 (7.6 – 17.2) 
Plasma NGAL (ng/mL) 55 (37 – 89) 
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Natriuretic peptides 
NT-proBNP (pg/mL) 3915 (2330 – 7391) 
BNP (pg/mL) 259 (106 – 505) 
ANP (ng/mL) 21 (13 – 31) 
Inflammatory markers 
CRP (µg/mL) 13.0 (5.5 – 27.9) 
MPO (ng/mL) 28 (23 – 35) 
TNFR1A (ng/mL) 1.1 (0.6 – 1.7) 
 
*N=446 
†Based on target guideline-recommended treatment doses37 
ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide; ALAT, alanine 
aminotransferase; ARB, angiotensin receptor blocker; ASAT, aspartate aminotransferase; 
BNP, brain natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration 
rate; HDL, high-density lipoprotein; HFpEF, heart failure with preserved ejection fraction; LDL, 
low-density lipoprotein; LVEF, left ventricular ejection fraction; MPO, myeloperoxidase; MRA, 
mineralocorticoid receptor antagonist; NGAL, neutrophil gelatinase-associated lipocalin; NT-
proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association; 
TNFR1A, tumor necrosis factor receptor 1 alfa  
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Table S4. Univariable regression analysis for determinants of HDL functionality. 
 Baseline 9 months  HDL functionality 
Variable Standardized 
beta 
T P-value Standardized 
beta 
T P-value Standardized 
beta 
T P-value 
HDL cholesterol efflux* 
Age -0.109 -2.305 0.022 -0.091 -1.788 0.075 -0.008 -0.153 0.879 
Female sex 0.025 0.528 0.598 0.055 1.069 0.286 0.001 0.024 0.981 
NYHA class II -0.432 -2.290 0.023 0.038 0.545 0.586 0.568 2.766 0.006 
NYHA class III -0.481 -2.522 0.012 -0.028 -0.400 0.689 0.540 2.636 0.009 
NYHA class IV -0.352 -2.738 0.006 0.063 1.190 0.235 0.290 2.168 0.031 
Systolic blood 
pressure 
0.019 0.397 0.692 0.058 1.137 0.256 0.032 0.626 0.532 
Diastolic blood 
pressure 
0.086 1.808 0.071 0.101 1.972 0.049 -0.026 -0.511 0.610 
Heart rate -0.089 -1.881 0.061 -0.009 -0.173 0.863 0.034 0.667 0.505 
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LVEF† 0.054 1.066 0.287 0.049 0.706 0.481 -0.016 -0.286 0.775 
Presence of 
diabetes 
0.029 0.605 0.546 -0.061 -1.198 0.232 -0.056 -1.102 0.271 
Never smoked 0.016 0.340 0.734 -0.056 -1.090 0.276 -0.063 -1.222 0.222 
Ischemic heart 
disease as 
primary HF 
etiology 
0.012 0.243 0.808 -0.026 -0.498 0.619 0.003 0.054 0.957 
Hypertension as 
primary HF 
etiology 
0.043 0.908 0.364 -0.117 -2.286 0.023 -0.111 -2.159 0.032 
Cardiomyopathy 
as primary HF 
etiology 
-0.030 -0.628 0.531 0.148 2.892 0.004 0.113 2.201 0.028 
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Valvular disease 
as primary HF 
etiology 
0.008 0.166 0.868 0.008 0.146 0.884 -0.040 -0.778 0.437 
ACE-inhibitor/ARB 
use 
-0.041 -0.866 0.387 0.030 0.582 0.561 0.071 1.399 0.163 
Beta blocker use 0.086 1.824 0.069 0.041 0.793 0.428 -0.003 -0.067 0.946 
Loop diuretic use 0.022 0.460 0.646 -0.074 -1.456 0.146 -0.005 -0.088 0.930 
MRA use 0.053 1.110 0.268 -0.016 -0.320 0.749 -0.013 -0.262 0.793 
Statin use 0.056 1.176 0.240 0.092 1.808 0.071 0.006 0.125 0.901 
Hemoglobin 0.144 3.024 0.003 0.074 1.195 0.233 -0.003 -0.050 0.960 
Sodium† 0.099 2.069 0.039 0.027 0.462 0.644 -0.007 -0.137 0.891 
Potassium† 0.065 1.368 0.176 -0.098 -1.694 0.091 0.014 0.269 0.788 
ASAT† -0.076 -1.314 0.190 0.061 0.771 0.442 0.061 0.977 0.330 
ALAT† -0.065 -1.203 0.230 0.087 1.213 0.227 0.063 1.079 0.282 
HDL cholesterol† 0.182 2.678 0.008 -0.048 -0.563 0.574 -0.067 -0.890 0.375 
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LDL cholesterol† 0.092 1.302 0.194 0.115 1.284 0.202 0.052 0.664 0.508 
Total cholesterol† 0.151 2.459 0.015 0.180 2.281 0.024 -0.014 -0.213 0.831 
Serum 
creatinine† 
-0.074 -1.573 0.116 -0.070 -1.228 0.220 -0.004 -0.072 0.943 
eGFR 0.092 1.949 0.052 0.092 1.613 0.108 -0.007 -0.136 0.892 
Urea† -0.086 -1.717 0.087 -0.092 -1.483 0.139 0.060 1.088 0.277 
Plasma NGAL† -0.066 -1.374 0.170 -0.159 -3.060 0.002 -0.057 -1.097 0.273 
NT-proBNP† -0.148 -3.044 0.002 -0.099 -1.112 0.268 -0.032 -0.613 0.540 
BNP† -0.099 -2.072 0.039 -0.133 -2.563 0.011 -0.027 -0.511 0.609 
ANP† -0.081 -1.687 0.092 -0.054 -1.034 0.302 0.009 0.174 0.862 
CRP† -0.193 -4.077 <0.001 -0.038 -0.717 0.474 0.083 1.611 0.108 
MPO† -0.064 -1.329 0.185 -0.058 -1.109 0.268 -0.058 -1.125 0.261 
TNFR1A† -0.132 -2.767 0.006 -0.118 -2.254 0.025 0.002 0.040 0.968 
Baseline HDL 
cholesterol efflux 
   -0.040 -0.777 0.438 -0.743 -21.670 <0.001 
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HDL anti-oxidative capacity 
Age -0.029 -0.621 0.535 0.045 0.871 0.385 0.056 1.102 0.271 
Female sex 0.046 0.964 0.335 0.006 0.124 0.901 -0.021 -0.417 0.677 
NYHA class II 0.163 0.859 0.391 0.005 0.071 0.944 -0.317 -1.532 0.126 
NYHA class III 0.203 1.060 0.290 0.004 0.054 0.957 -0.331 -1.603 0.110 
NYHA class IV 0.070 0.545 0.586 -0.019 -0.360 0.719 -0.179 -1.333 0.183 
Systolic blood 
pressure 
-0.061 -1.276 0.203 -0.036 -0.695 0.488 0.021 0.414 0.679 
Diastolic blood 
pressure 
-0.020 -0.431 0.667 -0.020 -0.388 0.698 -0.007 -0.141 0.888 
Heart rate 0.052 1.086 0.278 -0.070 -1.367 0.172 -0.052 -1.013 0.312 
LVEF† -0.025 -0.485 0.628 -0.065 -0.936 0.350 0.078 1.430 0.154 
Presence of 
diabetes 
-0.028 -0.599 0.550 0.005 0.095 0.924 0.026 0.514 0.607 
Never smoked -0.061 -1.289 0.198 -0.004 -0.075 0.940 0.060 1.162 0.246 
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Ischemic heart 
disease as 
primary HF 
etiology 
-0.042 -0.883 0.378 0.045 0.867 0.386 0.061 1.189 0.235 
Hypertension as 
primary HF 
etiology 
0.003 0.055 0.956 -0.042 -0.815 0.416 -0.017 -0.330 0.741 
Cardiomyopathy 
as primary HF 
etiology 
0.015 0.321 0.748 -0.083 -1.613 0.108 -0.062 -1.211 0.227 
Valvular disease 
as primary HF 
etiology 
-0.028 -0.595 0.552 0.025 0.487 0.626 0.025 0.479 0.632 
ACE-inhibitor/ARB 
use 
0.027 0.579 0.563 -0.093 -1.822 0.069 -0.115 -2.270 0.024 
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Beta blocker use -0.035 -0.742 0.459 -0.123 -2.422 0.016 -0.049 -0.957 0.339 
Loop diuretic use -0.076 -1.616 0.107 0.077 1.503 0.134 0.064 1.242 0.215 
MRA use 0.015 0.313 0.754 -0.011 -0.224 0.823 -0.016 -0.311 0.756 
Statin use -0.051 -1.068 0.268 0.126 2.477 0.014 0.071 1.397 0.163 
Hemoglobin -0.085 -1.764 0.078 0.123 1.976 0.049 0.021 0.411 0.681 
Sodium† -0.053 -1.112 0.267 0.034 0.579 0.563 0.060 1.154 0.249 
Potassium† -0.015 -0.323 0.747 -0.100 -1.730 0.085 -0.057 -1.101 0.272 
ASAT† 0.040 0.696 0.487 0.136 1.712 0.088 -0.015 -0.237 0.813 
ALAT† 0.048 0.883 0.378 0.080 1.106 0.270 -0.042 -0.710 0.479 
HDL cholesterol† 0.003 0.050 0.960 -0.014 -0.167 0.867 -0.065 -0.870 0.386 
LDL cholesterol† -0.096 -1.362 0.175 -0.015 -0.168 0.867 0.044 0.560 0.576 
Total cholesterol† -0.097 -1.569 0.118 -0.031 -0.389 0.698 -0.013 -0.199 0.843 
Serum 
creatinine† 
0.039 0.827 0.409 0.050 0.874 0.383 0.017 0.334 0.738 
eGFR -0.039 -0.816 0.415 -0.048 -0.839 0.402 -0.024 -0.459 0.646 
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Urea† -0.048 -0.955 0.340 -0.031 -0.507 0.612 0.052 0.942 0.347 
Plasma NGAL† 0.024 0.496 0.620 0.120 2.295 0.022 0.034 0.654 0.513 
NT-proBNP† 0.066 1.346 0.179 -0.095 -1.064 0.289 -0.036 -0.687 0.492 
BNP† 0.016 0.337 0.736 0.096 1.829 0.068 0.022 0.419 0.676 
ANP† 0.005 0.109 0.913 0.104 1.985 0.048 0.036 0.700 0.484 
CRP† 0.010 0.199 0.843 0.008 0.151 0.880 -0.014 -0.271 0.786 
MPO† -0.008 -0.171 0.864 0.004 0.069 0.945 0.046 0.895 0.371 
TNFR1A† 0.053 1.104 0.270 0.097 1.860 0.064 0.019 0.367 0.714 
Baseline anti-
oxidative capacity 
   -0.073 -1.423 0.156 -0.756 -22.510 <0.001 
HDL anti-inflammatory capacity 
Age 0.004 0.082 0.935 -0.066 -1.300 0.194 -0.054 -1.061 0.290 
Female sex 0.036 0.762 0.447 -0.033 -0.652 0.515 -0.057 -1.105 0.270 
NYHA class II -0.044 -0.233 0.816 0.079 1.126 0.261 0.066 0.318 0.750 
NYHA class III -0.064 -0.333 0.739 0.100 1.446 0.149 0.146 0.707 0.480 
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NYHA class IV -0.061 -0.473 0.636 -0.047 -0.894 0.372 0.038 0.284 0.777 
Systolic blood 
pressure 
0.032 0.676 0.500 0.155 3.053 0.002 0.041 0.797 0.426 
Diastolic blood 
pressure 
0.030 0.632 0.527 0.184 3.626 <0.001 -0.061 -1.190 0.235 
Heart rate 0.009 0.183 0.855 -0.155 -3.057 0.002 -0.063 -1.228 0.220 
LVEF† -0.001 -0.018 0.986 -0.072 -1.039 0.300 -0.019 -0.342 0.732 
Presence of 
diabetes 
-0.072 -1.517 0.130 0.061 1.189 0.235 0.100 1.965 0.050 
Never smoked -0.037 -0.774 0.439 -0.070 -1.359 0.175 -0.042 -0.829 0.408 
Ischemic heart 
disease as 
primary HF 
etiology 
0.010 0.208 0.835 0.048 0.934 0.351 0.046 0.898 0.370 
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Hypertension as 
primary HF 
etiology 
-0.009 -0.183 0.855 -0.104 -2.032 0.043 -0.091 -1.772 0.077 
Cardiomyopathy 
as primary HF 
etiology 
-0.052 -1.083 0.279 0.052 1.009 0.314 0.066 1.290 0.198 
Valvular disease 
as primary HF 
etiology 
-0.020 -0.412 0.681 -0.000 -0.008 0.994 0.023 0.436 0.663 
ACE-inhibitor/ARB 
use 
-0.044 -0.926 0.355 -0.031 -0.598 0.550 0.060 1.170 0.243 
Beta blocker use -0.005 -0.106 0.916 -0.027 -0.531 0.596 0.016 0.317 0.751 
Loop diuretic use 0.003 0.059 0.953 -0.052 -1.019 0.309 0.001 0.014 0.989 
MRA use 0.069 1.456 0.146 -0.018 -0.346 0.730 -0.023 -0.448 0.654 
Statin use -0.039 -0.823 0.411 0.038 0.744 0.458 0.092 1.805 0.072 
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Hemoglobin 0.021 0.444 0.657 0.048 0.768 0.443 -0.014 -0.271 0.786 
Sodium† -0.004 -0.076 0.940 -0.012 -0.204 0.839 -0.028 -0.532 0.595 
Potassium† 0.039 0.821 0.412 -0.001 -0.010 0.992 0.061 1.185 0.237 
ASAT† 0.030 0.523 0.601 0.040 0.501 0.617 0.013 0.210 0.834 
ALAT† 0.009 0.167 0.868 0.102 1.416 0.159 0.028 0.474 0.636 
HDL cholesterol† -0.071 -1.038 0.300 -0.093 -1.089 0.278 -0.070 -0.932 0.353 
LDL cholesterol† -0.018 -0.253 0.800 -0.105 -1.170 0.244 -0.027 -0.341 0.734 
Total cholesterol† -0.038 -0.616 0.538 -0.115 -1.452 0.149 -0.051 -0.766 0.445 
Serum 
creatinine† 
-0.032 -0.668 0.505 0.054 0.954 0.341 0.005 0.097 0.923 
eGFR 0.025 0.534 0.593 -0.028 -0.482 0.630 0.019 0.371 0.711 
Urea† -0.009 -0.185 0.853 0.006 0.090 0.928 0.044 0.811 0.418 
Plasma NGAL† 0.055 1.134 0.258 0.068 1.298 0.195 -0.016 -0.304 0.761 
NT-proBNP† -0.005 -0.096 0.924 0.045 0.499 0.619 -0.005 -0.009 0.992 
BNP† 0.001 0.022 0.982 0.031 0.593 0.554 0.051 0.987 0.324 
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ANP† -0.022 -0.457 0.648 -0.042 -0.795 0.427 -0.005 -0.090 0.929 
CRP† 0.066 1.377 0.169 0.004 0.084 0.933 -0.067 -1.287 0.199 
MPO† -0.001 -0.027 0.979 0.031 0.594 0.553 0.008 0.147 0.883 
TNFR1A† -0.002 -0.043 0.966 -0.019 -0.355 0.723 -0.006 -0.124 0.902 
Baseline anti-
inflammatory 
capacity 
   0.019 0.375 0.708 -0.524 -12.010 <0.001 
 
Cells in grey indicate that none of the available variables were determinants. 
*Log-transformed for baseline and 9 months. 
†Log transformed 
ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; CRP, C-
reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; NGAL, neutrophil gelatinase-
associated lipocalin; NT-proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association; TNFR1A, tumor necrosis factor 
receptor 1 alfa 
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Table S5. Multivariable linear regression analysis for determinants of HDL functionality  
 Baseline 9 months  HDL functionality 
Variable Standardized 
beta 
T P-value Standardized 
beta 
T P-value Standardized 
beta 
T P-value 
HDL cholesterol efflux* 
Age -0.211 -3.147 0.002       
HDL cholesterol† 0.207 3.089 0.003       
Total cholesterol†    0.178 2.286 0.024    
Hypertension as 
prim. HF etiology 
   -0.197 -2.539 0.012 -0.080 -2.338 0.020 
Baseline 
cholesterol 
efflux† 
      -0.746 -21.802 <0.001 
NYHA class II       0.212 3.729 <0.001 
NYHA class III       0.145 2.557 0.011 
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HDL anti-oxidative capacity‡ 
Beta blocker use    -0.141 -2.278 0.024    
Hemoglobin    0.137 2.210 0.028    
Baseline anti-
oxidative capacity 
      -0.751 -22.448 <0.001 
ACE-inhibitor use       -0.071 -2.122 0.035 
HDL anti-inflammatory capacity§ 
Heart rate†    -0.143 -2.805 0.005    
Systolic blood 
pressure 
   0.129 2.083 0.038    
Diastolic blood 
pressure 
   -0.126 -2.047 0.041    
Baseline anti-
inflammatory 
capacity 
      -0.524 -11.956 <0.001 
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Hypertension as 
prim. HF etiology 
      -0.089 -2.032 0.043 
Cells in grey indicate that none of the available variables were determinants. 
*Log-transformed for baseline and 9 months. Adjusted R2 models: baseline efflux, 0.068; 9 months, 0.059; delta: 0.574. 
†Log transformed 
‡Adjusted R2 models: anti-oxidative capacity 9 months: 0.027; delta: 0.574. 
§Adjusted R2 models: anti-inflammatory capacity 9 months: 0.029; delta: 0.279. 
ACE, angiotensin-converting enzyme; HDL, high-density lipoprotein; HF, heart failure; NYHA, New York Heart Association
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Figure S1. Differences in HDL functionality (relative to control) between baseline and 9 
months (unpaired). 
 
N (patients) = 446 at baseline, N (patients) = 383 at 9 months. P-values resulting from the Wilcoxon Rank Sum 
test for paired samples. A) HDL cholesterol efflux, P<0.001 B) Anti-oxidative capacity, P<0.001 C) Anti-
inflammatory capacity, P=0.046 D) HDL cholesterol concentration, P=0.040. 
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Figure S2. Differences in HDL functionality at baseline between heart failure with preserved 
ejection fraction and heart failure with reduced ejection fraction. 
 
A) HDL cholesterol efflux. Number of patients: 359 HFrEF, 31 HFpEF, P = 0.773 B) Anti-oxidative capacity. Number of 
patients: 359 HFrEF, 31 HFpEF, P = 0.683 C) Anti-inflammatory capacity. Number of patients: 359 HFrEF, 31 HFpEF, P = 0.431 
D) HDL cholesterol concentration. Number of patients: 183 HFrEF, 12 HFpEF, P = 0.215 
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Figure S3. Correlation plots showing associations among HDL functionality measures. 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 30, 2021
